Pulsenmore Ltd. (NASDAQ: PLSM)

Pulsenmore Ltd. is an emerging medical device company focused on the research, development, manufacture, marketing, and sale of innovative, non-invasive portable ultrasound solutions designed for home use. The company operates in the medical ultrasound industry, specifically targeting the home-based diagnostic imaging market with products that enable patients to perform self-scans under telehealth guidance for prenatal care, fertility treatments, and lung fluid monitoring. Its products connect to smartphones via a cradle and use proprietary software to capture, process, and transmit ultrasound images to healthcare providers for remote interpretation, eliminating the need for clinic visits for routine monitoring.

Pulsenmore generates revenue primarily through the sale of its ultrasound devices and associated services. Its flagship product, the Pulsenmore ES, is cleared for use in the United States, Europe, Switzerland, Australia, Brazil, Colombia, and Israel, enabling pregnant women to perform self-scans and telehealth-guided scans at home to capture fetal heartbeat, amniotic fluid levels, and other prenatal indicators. The Pulsenmore FC supports self-examination of ovarian follicles and endometrial tissue for women undergoing in vitro fertilization procedures, while the Pulsenmore MC is under development for daily monitoring of lung fluid in patients with pulmonary conditions, end-stage renal disease, or congestive heart failure. Revenue is driven by sales to healthcare organizations, with strategic partnerships with Clalit and Sheba accounting for approximately 96% of overall revenue for the year ended December 31, 2025, through distribution of Pulsenmore ES units to patients. The company reported total revenue of approximately $2.9 million from these Israeli partnerships alone in 2025, reflecting strong adoption of its home ultrasound solution.

Pulsenmore positions itself as an innovator in the home ultrasound market, offering what it believes to be the only ultrasound product intended for use by lay persons in non-clinical settings. While competing with established players like GE Healthcare's VScan and Butterfly Network's IQ+, the company differentiates through its focus on patient-operated devices that require no prior medical training. Its competitive advantages include a user-friendly interface and design that ensures patient safety and comfort, affordability relative to traditional clinic-based systems that cost between $45,000 and $100,000 per device, and a strong intellectual property portfolio comprising 31 granted patents and 63 pending patent applications as of March 15, 2026. The company cites market research indicating the global prenatal, fetal, and neonatal equipment market was valued at approximately $4.2 billion in 2024 and is projected to reach $7.1 billion by 2033, highlighting the addressable opportunity for its solutions.

The company's customer base includes health maintenance organizations, hospitals, and healthcare providers that distribute its devices to patients. Specific customers named in the filing are Clalit, Israel's largest health maintenance organization, which purchased 6,915 Pulsenmore ES units in 2025 for distribution to prenatal patients, and Sheba Medical Center, which received 110 Pulsenmore ES units for the same purpose in 2025. Pulsenmore also maintains distribution agreements with partners in Italy, France, and Poland, has established a collaboration with Gold Coast University Hospital in Australia for clinical evaluation, and is actively expanding its commercial footprint in the United States following FDA clearance of the Pulsenmore ES as a Class II device in October 2025 to enable fetal heartrate assessment. The company targets patients with high-risk pregnancies initially, representing approximately 20% of annual births, with plans to expand to broader populations as it seeks to capitalize on the estimated 140 million annual births worldwide.